A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.

Bae CY, Cho CY, Cho K, Hoon Oh B, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi GD, Cho H, Lee H

Journal of the American Geriatrics Society1 Dec 2000Cited by 31 (Europe PMC)

PMID11129744DOI10.1111/j.1532-5415.2000.tb03865.xPepBankPUB-11129744

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with mild to moderate Alzheimer's disease, Cerebrolysin improved ADAS-Cog scores versus placebo (P = .02).
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin improved cognitive scores more than placebo.
Peptide
Cerebrolysin
Outcome
DecreaseADAS-Cog
Study
n = 53
Comparator
Placebo
Analysis
Primary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
ADAS-Cog comparison p value
0.02 p value
Cerebrolysin versus placebo, ADAS-Cog, after 4 weeks
Source sentences
Summary
After 4 weeks of treatment, Cerebrolysin-treated patients demonstrated significant improvements in the ADAS-Cog (P = .02), CGIS/C (P = .01), and MMSE (P = .04) compared with placebo-treated patients.
6 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Clinical Global Impression of Severity/ Change (CGIS/C).
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974401
02HumanRandomized controlled trialEfficacy outcome
In patients with mild to moderate Alzheimer's disease, Cerebrolysin improved CGIS/C scores versus placebo (P = .01).
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin improved global clinical ratings more than placebo.
Peptide
Cerebrolysin
Outcome
DecreaseCGIS/C
Study
n = 53
Comparator
Placebo
Analysis
Primary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
CGIS/C comparison p value
0.01 p value
Cerebrolysin versus placebo, CGIS/C, after 4 weeks
Source sentences
Summary
After 4 weeks of treatment, Cerebrolysin-treated patients demonstrated significant improvements in the ADAS-Cog (P = .02), CGIS/C (P = .01), and MMSE (P = .04) compared with placebo-treated patients.
6 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Clinical Global Impression of Severity/ Change (CGIS/C).
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974402
03HumanRandomized controlled trialEfficacy outcome
In patients with mild to moderate Alzheimer's disease, Cerebrolysin improved MMSE scores versus placebo (P = .04).
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin improved mental examination scores more than placebo.
Peptide
Cerebrolysin
Outcome
IncreaseMMSE
Study
n = 53
Comparator
Placebo
Analysis
Secondary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
MMSE comparison p value
0.04 p value
Cerebrolysin versus placebo, MMSE, after 4 weeks
Source sentences
Summary
After 4 weeks of treatment, Cerebrolysin-treated patients demonstrated significant improvements in the ADAS-Cog (P = .02), CGIS/C (P = .01), and MMSE (P = .04) compared with placebo-treated patients.
6 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Katz Index of Activities of Daily Living (ADL), and Lawton Instrumental Activities of Daily Living (IADL) Scale.
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974403
04HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer's disease, Cerebrolysin did not significantly improve GDS scores versus placebo.
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin did not significantly improve depression scores compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeGeriatric Depression Scale
Study
n = 53
Comparator
Placebo
Analysis
Secondary
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
Source sentences
Summary
However, there were no significant improvements in the Cerebrolysin group compared with the placebo group on the GDS, ADL, and IADL.
6 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Katz Index of Activities of Daily Living (ADL), and Lawton Instrumental Activities of Daily Living (IADL) Scale.
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974407
05HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer's disease, Cerebrolysin did not significantly improve ADL scores versus placebo.
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin did not significantly improve daily activities compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeActivities of daily living
Study
n = 53
Comparator
Placebo
Analysis
Secondary
Outcome group
Exercise and physical function · Whole body
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
Source sentences
Summary
However, there were no significant improvements in the Cerebrolysin group compared with the placebo group on the GDS, ADL, and IADL.
6 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Katz Index of Activities of Daily Living (ADL), and Lawton Instrumental Activities of Daily Living (IADL) Scale.
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974408
06HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer's disease, Cerebrolysin did not significantly improve IADL scores versus placebo.
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin did not significantly improve instrumental daily activities compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeInstrumental activities of daily living
Study
n = 53
Comparator
Placebo
Analysis
Secondary
Outcome group
Exercise and physical function · Whole body
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
Source sentences
Summary
However, there were no significant improvements in the Cerebrolysin group compared with the placebo group on the GDS, ADL, and IADL.
6 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Katz Index of Activities of Daily Living (ADL), and Lawton Instrumental Activities of Daily Living (IADL) Scale.
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974409
07HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer's disease, ADAS-Cog improved in 82% with Cerebrolysin versus 31.6% with placebo.
In plain wordsIn patients with Alzheimer's disease, more Cerebrolysin patients improved on cognitive testing than placebo patients.
Peptide
Cerebrolysin
Outcome
IncreaseADAS-Cog improvement proportion
Study
n = 53
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Improved
82%
Cerebrolysin ADAS-Cog
Improved
31.6%
placebo ADAS-Cog
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
Source sentences
Summary
Among Cerebrolysin-treated patients, 82%, 62%, and 44% were rated improved on ADAS-Cog, CGIS/C, and MMSE, respectively, compared with 31.6%, 22%, and 17% of placebo-treated patients, respectively.
6 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Clinical Global Impression of Severity/ Change (CGIS/C).
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974404
08HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer's disease, CGIS/C improved in 62% with Cerebrolysin versus 22% with placebo.
In plain wordsIn patients with Alzheimer's disease, more Cerebrolysin patients improved on global clinical ratings than placebo patients.
Peptide
Cerebrolysin
Outcome
IncreaseCGIS/C improvement proportion
Study
n = 53
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Improved
62%
Cerebrolysin CGIS/C
Improved
22%
placebo CGIS/C
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
Source sentences
Summary
Among Cerebrolysin-treated patients, 82%, 62%, and 44% were rated improved on ADAS-Cog, CGIS/C, and MMSE, respectively, compared with 31.6%, 22%, and 17% of placebo-treated patients, respectively.
6 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Clinical Global Impression of Severity/ Change (CGIS/C).
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974405
09HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer's disease, MMSE improved in 44% with Cerebrolysin versus 17% with placebo.
In plain wordsIn patients with Alzheimer's disease, more Cerebrolysin patients improved on mental examination scores than placebo patients.
Peptide
Cerebrolysin
Outcome
IncreaseMMSE improvement proportion
Study
n = 53
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Improved
44%
Cerebrolysin MMSE
Improved
17%
placebo MMSE
Cerebrolysin group sample size
34 patients
Cerebrolysin group, 4-week comparison
Placebo group sample size
19 patients
placebo group, 4-week comparison
Source sentences
Summary
Among Cerebrolysin-treated patients, 82%, 62%, and 44% were rated improved on ADAS-Cog, CGIS/C, and MMSE, respectively, compared with 31.6%, 22%, and 17% of placebo-treated patients, respectively.
6 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Katz Index of Activities of Daily Living (ADL), and Lawton Instrumental Activities of Daily Living (IADL) Scale.
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Summary · context
The control group (n = 19) received placebo.
Summary · context
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
Report a problemFND-1112974406
10HumanRandomized controlled trialSafety outcome
In patients with Alzheimer's disease, neither the Cerebrolysin group nor the placebo group had dropouts.
In plain wordsIn patients with Alzheimer's disease, no patients discontinued Cerebrolysin or placebo.
Peptide
Cerebrolysin
Outcome
Not applicableDropouts
Study
n = 53
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Source sentences
Summary
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Report a problemFND-1112974410
11HumanRandomized controlled trialOther
In patients with Alzheimer's disease, compliance was 100% with both Cerebrolysin and placebo.
In plain wordsIn patients with Alzheimer's disease, all patients complied with Cerebrolysin or placebo treatment.
Peptide
Cerebrolysin
Outcome
Not applicableTreatment compliance
Study
n = 53
Comparator
Placebo
Outcome group
Treatment adherence and retention · Whole body
Studied dose
30 mL once a day from Monday to Friday · IV · 4 weeksAs given in this study (human).
Measurements
Compliance
100%
Cerebrolysin and placebo
Source sentences
Summary
There were no dropouts in either groups, with 100% compliance to Cerebrolysin and placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
A 4-week randomized, double-blind, placebo-controlled, multicenter clinical trial.
Summary · context
Fifty-three men and women at least 50 years of age admitted to hospitals with mild to moderate AD and otherwise in good health.
Summary · context
The treatment group (n = 34) received Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks.
Report a problemFND-1112974411

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

WithdrawnPhase 4NCT01822951

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)

Ever Neuro Pharma GmbHn = 0Completion est. Dec 2016

Alzheimer Disease

Trial page ClinicalTrials.govUpdated 26 Oct 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.